Guyasuta Investment Advisors Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 105,801 shares of the medical research company’s stock after acquiring an additional 1,082 shares during the period. Thermo Fisher Scientific comprises about 3.8% of Guyasuta Investment Advisors Inc.’s portfolio, making the stock its 3rd largest holding. Guyasuta Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $53,373,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in TMO. Viking Global Investors LP lifted its holdings in shares of Thermo Fisher Scientific by 1,007.6% in the first quarter. Viking Global Investors LP now owns 861,887 shares of the medical research company’s stock valued at $393,348,000 after purchasing an additional 784,070 shares in the last quarter. Morgan Stanley raised its holdings in shares of Thermo Fisher Scientific by 7.3% during the first quarter. Morgan Stanley now owns 8,293,242 shares of the medical research company’s stock worth $3,784,871,000 after acquiring an additional 566,814 shares in the last quarter. Flossbach Von Storch AG raised its holdings in shares of Thermo Fisher Scientific by 130.6% during the second quarter. Flossbach Von Storch AG now owns 796,673 shares of the medical research company’s stock worth $401,898,000 after acquiring an additional 451,134 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Thermo Fisher Scientific by 10.6% during the second quarter. Bank of New York Mellon Corp now owns 3,993,588 shares of the medical research company’s stock worth $2,014,647,000 after acquiring an additional 381,863 shares in the last quarter. Finally, AMF Pensionsforsakring AB purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $166,477,000. Institutional investors own 85.50% of the company’s stock.
In other news, Director Jim P. Manzi sold 572 shares of the business’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $536.54, for a total transaction of $306,900.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 4th. The stock was sold at an average price of $539.05, for a total transaction of $5,390,500.00. The disclosure for this sale can be found here. Insiders own 0.44% of the company’s stock.
Shares of Thermo Fisher Scientific stock traded down $21.61 during midday trading on Monday, reaching $588.17. The company had a trading volume of 35,152 shares, compared to its average volume of 1,604,801. The company has a current ratio of 2.78, a quick ratio of 2.11 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $231.40 billion, a price-to-earnings ratio of 28.27, a price-to-earnings-growth ratio of 1.33 and a beta of 0.74. The stock has a fifty day simple moving average of $554.00 and a 200 day simple moving average of $502.12. Thermo Fisher Scientific Inc. has a 1-year low of $412.80 and a 1-year high of $616.93.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 28th. The medical research company reported $5.60 EPS for the quarter, topping analysts’ consensus estimates of $5.51 by $0.09. Thermo Fisher Scientific had a net margin of 22.47% and a return on equity of 29.43%. The firm had revenue of $9.27 billion during the quarter, compared to analyst estimates of $8.75 billion. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 22.07 earnings per share for the current year.
Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback program on Thursday, September 23rd that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 1.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 15th. Shareholders of record on Wednesday, September 15th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $1.04 annualized dividend and a yield of 0.18%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 5.32%.
About Thermo Fisher Scientific
Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Further Reading: Forex
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.